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Introduction Objective Methodology
What bioequivalencemeans?
When the patent of a new drug is due, generic drug
clones come into the market. Generic drugs are enforced
to have the same active ingredients, route of
administration, and dosage form as the branded product
but there are no specific requirements for the salts. Thus
generic drugs must prove to be bioequivalent to the
branded drug before they can be authorised and
marketed.
• Verify whether there is or not a difference regarding the
effectivity of the branded drug and their generics and also if
they can be considered interchangeable.
• Examine the usage of different salts within the various
generic formulations to check if they could modify the
properties of the drug composition and its effectiveness and
safety.
The methodology consisted on the review through literature research of journal articles
based on the case of a drug approved in the Spanish market. In detail a commercial
best‐selling drug with clinical trials available was selected (Plavix®), whose active
ingredient is clopidogrel binded with hydrogen sulphate salt.
As for the generic drug clones, the approval for selling them into the market comes
with three distinct salts (besylate, hydrochloride and hydrogen sulphate), therefore
studies accounting for each type of salt have been reviewed to confirm if there is any






























Figure 2. Bioavailability: Drug
concentration versus time. AUC:
curves for two drug products. area
under the curve of the drug's
concentration in the blood with
 

































































































 Clopidogrel is a drug used as the primary choice for the treatment and prevention of ACS
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• From the result of the literature review, it can be concluded that the statistical difference of
+/‐ 20% of AUC in the bioavailability of the bioequivalence studies does not change the
effectiveness of the generic drug against the branded one.
• Branded and generic drugs are fully interchangeable: No differences in the pharmacokinetics
and pharmacodynamic effects between the generic and the branded drugs were found.
• The fact that different salts were used on the branded and the generic drug equivalent is
 op ogre s part o t e p ate et ant aggregant group.
 Clopidogrel is a derivative of tienopyridine a prodrug which requires to be activated through the
multiples hepatic cytochromes (CYP) P450s mainly the CYP3A4 and CYP3A4 isoform and the
isoenzyme CYP2C19 in order to perform its platelet antiaggregant activity.
This activity is performed via a selective and irreversible bonding with the platelet P2Y12 receptor of
the adenosine diphosphate (ADP). As a consequence, the activation of the complex glycoprotein
(GPIIb‐GPIIIa) that is fired through ADP as the molecule in charge of the platelet antiaggregation, is
inhibited.
Conclusions
independent of the bioavailability.
• A recommendation for the bioequivalence studies would be the selection of patients both
healthy and with diseases. It is also important to take into account that both type of patients
must have genetic traits as similar as possible in order to minimize the factors that could
influence bioavailability.
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Figure 4. Activation and mechanism of action of clopidogrel2.
